Thrombocytosis portends adverse prognostic significance in patients with stage II colorectal carcinoma by Guo, Tianhua et al.
 
Thrombocytosis portends adverse prognostic significance in
patients with stage II colorectal carcinoma
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Guo, Tianhua, Marcin Krzystanek, Zoltan Szallasi, and Arpad
Szallasi. 2014. “Thrombocytosis portends adverse prognostic
significance in patients with stage II colorectal carcinoma.”
F1000Research 3 (1): 180. doi:10.12688/f1000research.4856.2.
http://dx.doi.org/10.12688/f1000research.4856.2.
Published Version doi:10.12688/f1000research.4856.2
Accessed February 17, 2015 9:20:18 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:13581264
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAF1000Research
Open Peer Review
, Sault Area Ioannis A. Voutsadakis
Hospital Canada
, Semmelweis University Judit Moldvay
Hungary
Discuss this article
 (0) Comments
2
1
OBSERVATION ARTICLE
   
Thrombocytosis portends adverse prognostic significance in
  patients with stage II colorectal carcinoma[v2; ref status: indexed, 
http://f1000r.es/4k6]
Tianhua Guo ,      Marcin Krzystanek , Zoltan Szallasi , Arpad Szallasi1
Department of Pathology, Monmouth Medical Center, Long Branch, NJ, NJ 07740, USA
Department of Systems Biology, Technical University of Denmark, Lyngby, 2800, Denmark
Children’s Hospital Informatics Program at the Harvard–Massachusetts Institute of Technology Division of Health Sciences and Technology,
Harvard Medical School, Boston, MA, MA 02115, USA
Abstract
Thrombocytosis portends adverse prognostic significance in many types of
cancers including ovarian and lung carcinoma. In this study, we determined the
prevalence and prognostic significance of thrombocytosis (defined as platelet
count in excess of 400 × 10 /μl) in patients with colorectal cancer. We
performed a retrospective analysis of 310 consecutive patients diagnosed at
our Institution between 2004 and 2013. The patients (48.7% male and 51.3%
female) had a mean age of 69.9 years (+/- 12.7 years) at diagnosis.
Thrombocytosis was found in a total of 25 patients, with a higher incidence in
those with stage III and IV disease (14.4% of patients). Although the mean
platelet count increased with the depth of tumor invasion (pT), its values
remained within normal limits in the whole patient cohort. No patient with stage I
cancer (n=57) had elevated platelet count at diagnosis. By contrast, five of the
78 patients (6.4%) with stage II cancer showed thrombocytosis, and four of
these patients showed early recurrence and/or metastatic disease, resulting in
shortened survival (they died within one year after surgery). The incidence of
thrombocytosis increased to 12.2% and 20.6%, respectively, in patients with
stage III and IV disease. The overall survival rate of patients with
thrombocytosis was lower than those without thrombocytosis in the stage II and
III disease groups, but this difference disappeared in patients with stage IV
cancer who did poorly regardless of their platelet count. We concluded that
thrombocytosis at diagnosis indicates adverse clinical outcome in colorectal
cancer patients with stage II or III disease. This observation is especially
intriguing in stage II patients because the clinical management of these patients
is controversial. If our data are confirmed in larger studies, stage II colon cancer
patients with thrombocytosis may be considered for adjuvant chemotherapy.
1 2 2,3 1
1
2
3
    Referee Status:
  Invited Referees
 
  
version 2
published
20 Oct 2014
version 1
published
31 Jul 2014
  1 2
report
report
report
report
 31 Jul 2014,  :180 (doi:  ) First published: 3 10.12688/f1000research.4856.1
 20 Oct 2014,  :180 (doi:  ) Latest published: 3 10.12688/f1000research.4856.2 v2
3
Page 1 of 11
F1000Research 2014, 3:180 Last updated: 10 NOV 2014F1000Research
 Arpad Szallasi ( ) Corresponding author: aszallasi@barnabashealth.org
 Guo T, Krzystanek M, Szallasi Z and Szallasi A.  How to cite this article: Thrombocytosis portends adverse prognostic significance in
   2014,  :180 (doi:  patients with stage II colorectal carcinoma [v2; ref status: indexed,  ] http://f1000r.es/4k6 F1000Research 3
) 10.12688/f1000research.4856.2
 © 2014 Guo T  . This is an open access article distributed under the terms of the  , which Copyright: et al Creative Commons Attribution Licence
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article
are available under the terms of the   (CC0 1.0 Public domain dedication). Creative Commons Zero "No rights reserved" data waiver
 The author(s) declared that no grants were involved in supporting this work. Grant information:
  Competing interests: No competing interests were disclosed.
 31 Jul 2014,  :180 (doi:  )  First published: 3 10.12688/f1000research.4856.1
 10 Nov 2014,  :180 (doi:  ) First indexed: 3 10.12688/f1000research.4856.2
Page 2 of 11
F1000Research 2014, 3:180 Last updated: 10 NOV 2014Introduction
Platelets play important roles in hemostasis, immunity and inflam-
mation1. Reactive thrombocytosis is an elevated platelet count 
(> 400 × 103/μl) that develops secondary to another disorder. Some 
causes of reactive thrombocytosis include iron deficiency, acute 
infection, and chronic inflammatory disorders (http://www.patient.
co.uk/doctor/thrombocytosis). Cancer is often associated with para-
neoplastic thrombocytosis2. Thrombocytosis was reported as a poor 
prognostic indicator in many types of cancers including lung can-
cer3, renal cell carcinoma4 and gynecological cancers5. A positive 
correlation between the depth of tumor invasion and platelet counts 
was demonstrated in a gastric cancer study, and thrombocytosis 
served as an adverse prognostic factor in clinical outcome in gastric 
cancer patients6. Recent studies have shown that thrombocytosis in 
cancer may be correlated with serum cytokine levels that stimulate 
thrombopoiesis. For example, elevated plasma levels of IL-6 and 
thrombopoietin were reported in ovarian cancer patients5.
Colon cancer is a leading cause of cancer-related death in devel-
oped countries (http://seer.cancer.gov/statfacts/html/colorect.html). 
A significant portion of patients receiving potentially curative resec-
tion dies within five years of diagnosis7. Since both chemo- and 
radiation therapies cause very significant side-effects, it is critical 
to define reliable prognostic factors to identify patients who might 
benefit from more aggressive adjuvant treatment options. The prog-
nostic role of thrombocytosis in colorectal cancer patients has not 
been fully investigated, although there are some reports supporting 
the negative impact of thrombocytosis on the survival of patients 
with colorectal cancer8,9.
In this study, the aim was to analyze the association between plate-
let count at diagnosis or pre-surgery and cancer stage, and to deter-
mine the prognostic significance of thrombocytosis in patients with 
colorectal cancer.
Patients and methods
After approval by the Monmouth Medical Center Institutional 
Research Review Board (IRB Study # 213-041), the medical records 
of 310 consecutive colorectal cancer patients who underwent 
biopsy (47 patients), surgical resection and/or neoadjuvant treat-
ment (263 patients) at our Institution between 2004 and 2013 were 
retrospectively reviewed. The patient cohort included 62 patients 
with in-situ or stage I disease, 78 patients at stage II, 98 patients at 
stage III, 34 patients at stage IV, and 38 patients with biopsy diag-
nosis only (stage could not be determined). The mean age of the 
patients was 69.9 ± 12.7 years (range = 32 to 98 years). The data 
gathered included platelet counts, tumor location, histological type 
and differentiation, lymph node metastasis, depth of tumor invasion 
(T), and presence or absence of distant metastasis. The database did 
not include ethnicity, smoking habits, and comorbidities. 
Pre-operative platelet counts were collected from our Laboratory 
Information System (LIS), and thrombocytosis was defined as plate-
let count ≥ 400 × 103/μl (normal range = 150 to 400 × 103/μl). After 
resection of the tumor, all specimens were histologically examined 
by a pathologist and the pathological TNM stage was determined 
according to the American Joint Committee on Cancer, 7th edition. 
Stage I and II cancers are lymph node negative (N0) whereas stage 
III is defined by the presence of lymph node metastasis. Patients 
with distant metastatic disease are classified as stage IV.
Survival data for 253 patients were provided by the Cancer Registry 
at the Leon Hess Cancer Center, Monmouth Medical Center (57 
patients were lost to follow-up). All calculations were made using 
R version 2.15.0 and packages “beeswarm”, “survplot”, “survival” 
and “stats”. Survival curves were generated using the Kaplan-Meier 
method. Hazard ratios with 95% confidence intervals were obtained 
using Cox proportional hazards regression. Long-rank test was 
used for the analysis of significance.
Results
The characteristics (including age, gender, pT stage, tumor dif-
ferentiation and platelet count) of the patients in our study cohort 
are shown in Table 1. Of the 310 patients with colorectal cancer, 
25 (8.1%) had thrombocytosis at diagnosis or pre-surgery with the 
highest incidence detected in stage IV patients (20.6%) [Table 2]. 
Importantly, none of the 57 patients with stage I carcinoma had ele-
vated platelet count. The mean platelet counts (× 103/μL) in patients 
with or without thrombocytosis were 494.7 ± 83.0 and 246.2 ± 
72.3, respectively.
Although the mean platelet count increased with the depth of inva-
sion (pT), it remained within the normal limits in all patients groups 
(pT1 to pT4) [Figure 1]. Mean platelet counts (× 103/μL) were 
      Amendments from Version 1
We are grateful to the referees for their time and efforts in improving 
our manuscript. Whereas we share some of the reservations of the 
referees, we would like to point out that this is an Observational 
Study and not a full report. We agree that our observations need 
to be confirmed in a much larger cohort of patients (indeed, we 
emphasize this upfront in the Abstract). That said, we believe that 
despite the study limitations our conclusions are sound enough for 
publication as a preliminary report.
In the revised version, major changes include: 
1) The major limitations of this study (small number of patients in 
the stage II group; no information on ethnicity, smoking history, 
medications and/or comorbidities) are now clearly stated in Patients 
and Methods.
2) The discrepancy in patient numbers between text/Tables and 
Figure 2 is now explained: our database contained 310 patients, 
however, our Cancer Registry contained survival data only on 253 
of these patients (the remaining 57 patients most likely decided to 
seek treatment at another medical facility and were, thus, lost to 
our follow-up).
3) Multivariate analysis was done (see Results). With regard to tumor 
location (right-sided versus left-sided cancer), the results are now 
detailed in the text.
4) Reactive thrombocytosis is now defined and its most common 
causes are listed in Introduction.
5) Reference range as well as mean platelet count (+/- SD) are now 
given for the two patient groups (with and without thrombocytosis).
6) As suggested, both Abstract and Discussion have been 
modified by changing “treated as stage III” to “may be considered 
for adjuvant chemotherapy”.
See referee reports
REVISED
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F1000Research 2014, 3:180 Last updated: 10 NOV 2014216 ± 71 (pT1), 252 ± 83 (pT2), 274 ± 109 (pT3), and 291 ± 104 
(pT4); this increase was significant at P = 0.001. By contrast, in 
multivariate analysis, there were no significant differences in 
thrombocytosis with regard to gender, age, location, or tumor dif-
ferentiation (data not shown). For example, our database included 
193 patients with right-sided (from cecum to splenic flexure) and 
102 patients with left-sided (from splenic flexure to rectosigmoid 
colon) cancer. Furthermore, we had one patient with rectal adeno-
carcinoma and 14 patients with metastatic (stage IV) colorectal car-
cinoma of unknown (at least to us) primary location. Fourteen of 
the 193 patients with right-sided (~7%) and 8 of the 102 patients 
with left-sided (~7%) carcinoma showed thrombocytosis at diagno-
sis, indicating that thrombocytosis is not predictive of the location 
of the tumor (right- versus left-sided).
The combined incidence of thrombocytosis in stage III and IV dis-
ease was 14.4%. Stage II disease had the lowest incidence (6.4%) 
and stage IV cancer showed the highest incidence of elevated 
platelet count (20.6%) [Table 2]. The overall survival of patients 
with stage I to stage III colorectal cancer with thrombocytosis was 
significantly lower than those without thrombocytosis [Figure 2]. 
Although patients with Stage IV carcinoma had the highest preva-
lence of thrombocytosis, these patients did uniformly poorly and 
the difference in survival was no longer observed in patients with 
or without elevated platelet count (not shown). Patients with throm-
bocytosis (PLT ≥ 400 × 103/μL) at stage I to stage III had a hazard 
ratio of 2.2 compared to the patients without thrombocytosis (PLT 
< 400 × 103/μL) as shown in Figure 2.
Dataset 1. Data of thrombocytosis in colon cancer patients
http://dx.doi.org/10.5256/f1000research.4856.d33371
This data set contains the medical records of patients diagnosed 
with colon cancer at the Monmouth Medical Center between 2004 
and 2013.
Table 1. Patient characteristics.
Number (%)
Total 310
Gender
   Male 151 (48.7%)
   Female 159 (51.3%)
Age 69.9 ± 12.7 yearsa
Pathologic category of primary tumor (pT)b
   pTis 5 (1.6%)
   pT1 17 (5.5%)
   pT2 60 (19.4%)
   pT3 137 (44.2%)
   pT4 44 (14.2%)
   pTx (unclassified) 47 (15.2%)
Gradec
   well differentiated 42 (13.5%)
   moderately differentiated 149 (48.1%)
   poorly differentiated 67 (21.6%)
   unclassified 52 (16.8%)
Platelet count (× 103/µL)
   ≥ 400 25 (8.1%)
   < 400 285 (91.9%)
a: Data presented as mean ± SD; b: staging according 
to AJCC Cancer Staging Manual 7th Edition); c: Grading 
according to WHO grading system
Table 2. Incidence of thrombocytosis in each stage of colorectal cancer.
Number of 
cases with 
thrombocytosis
Number of 
cases without 
thrombocytosis
Total 
number 
of cases
% of 
thrombocytosis
Stage 0 0 5 5 0.0
Stage I 0 57 57 0.0
Stage II 5 73 78 6.4
Stage III 12 86 98 12.2
Stage IV 7 27 34 20.6
Stage X 
(unclassified) 1 37 38 2.6
Overall 25 285 310 8.1
*Stage IV and III 
combined 19 113 132 14.4
Note: There are 403 cases in our data pool. 310 cases were diagnosed as colon cancer among the 
321 cases with available platelet counts (82 cases without platelet counts). 11 non-colorectal cancer 
cases including 5 cases labeled as “appendix” and 6 cases labeled as “not colon cancer” were taken 
out of the pool.
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Patients were allocated into two groups: with thrombocytosis, PLT ≥ 400 × 103/µL (labeled as Exceeds) and without thrombocytosis) PLT 
< 400 × 103/µL (labeled as Normal). The patients with thrombocytosis have a hazard ratio of 1.8 compare to the patients without thrombocytosis 
(P<0.041).
02 04 06 08 01 00
0
.
0
0
.
2
0
.
4
0
.
6
0
.
8
1
.
0
Time (months)
O
v
e
r
a
l
l
 
S
u
r
v
i
v
a
l
 
(
p
r
o
b
a
b
l
i
l
i
t
y
)
Thrombocytosis
No
Yes
HR = 1.8 (1.0 − 3.3)
logrank P = 0.041
Number at risk
232 114 74 45 17 3 No
21 87300 Yes     
Figure 1. Mean platelet count according to the depth of tumor invasion. The mean platelet count of patients with pT1, (216 ± 71) × 103/µL 
is significantly lower than patients with pT4 (291 ± 104) × 103/µL, P = 0.001.
Discussion
It was noted more than 100 years ago that thrombocytosis is often 
seen in patients with malignant diseases. Indeed, thrombocytosis 
correlates with both worse disease free survival and shortened over-
all survival in patients with ovarian cancer5, and worsens overall 
survival in patients with gastric cancer (reviewed in 10). The prog-
nostic significance of thrombocytosis in colorectal cancer, however, 
remains controversial11, although the majority of literature suggests 
a negative impact of thrombocytosis on the survival of patients with 
colorectal cancer8,9.
In the present study, we identified a mild, T stage-dependant 
increase in mean platelet counts in patients with colorectal carci-
noma that reached statistical significance when comparing T1 to T4; 
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however, the mean platelet count remained within the normal lim-
its in the whole patient cohort. Importantly, thrombocytosis was 
more common among patients with advanced disease: its preva-
lence increased from 6.4% in stage II to 20.6% in stage IV cancer 
patients. Our data are comparable to those reported in the literature 
(12.1–13.9%;7,8).
In our study, thrombocytosis showed adverse prognostic signifi-
cance in patients with stage I to stage III colorectal carcinoma; this 
was no longer apparent in patients with stage IV disease, presum-
ably because these patients did poorly regardless of the platelet 
count.
Probably the most intriguing observation of our study is the fairly 
uniformly dismal clinical outcome of stage II patients with throm-
bocytosis (five out of 78 patients): four of these five patients did 
very poorly (they died within a year) and the fifth was lost to fol-
low-up. At present, the National Comprehensive Cancer Network 
guidelines do not recommend routine administration of adjuvant 
chemotherapy to stage II colorectal cancer patients whose cancer 
was completely resected12. Clearly, the small number of patients in 
this group precludes a definitive conclusion. However, if confirmed 
in future larger studies, our data indicate that stage II colorectal 
cancer patients with thrombocytosis may benefit from adjuvant 
chemotherapy.
The molecular mechanisms underlying thrombocytosis in cancer 
patients are incompletely understood. Recently, plasma levels of 
IL-6 and thrombopoietin were found to significantly correlate with 
platelet counts in ovarian cancer patients5. Indeed, silencing of the 
IL-6 and thrombopoietin genes markedly abrogated thrombocytosis 
(and halted tumor progression) in a mouse model of epithelial ovar-
ian cancer5. These findings are promising because an anti-IL-6 agent 
(siltuximab) has already been approved by the United States Food 
and Drug Administration (FDA) to treat patients with Castleman’s 
disease (http://www.cancer.org//cancer/new/fda-approves-sylvant-
siltuximab-for-castleman-disease). Another series of study showed 
that immobilized platelets support human colon carcinoma cell teth-
ering, rolling, and firm adhesion under dynamic flow conditions in 
colon cancer cell lines, suggesting a role of platelets in hematoge-
nous dissemination of tumor cells in colorectal cancer13. Taken together, 
these studies imply that inhibition of thrombocytosis may represent a 
potential novel target in cancer therapy.
In summary, thrombocytosis appears to herald adverse clinical out-
come in patients with stage II and III colorectal carcinoma. We sug-
gest that elevated platelet count may identify a subset of patients 
with stage II colon cancer who could benefit from close follow-up 
and adjuvant chemotherapy.
Data availability
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doi:10.5256/f1000research.5910.r6678
  Ioannis A. Voutsadakis
Medical Oncology, Sault Area Hospital, Ontario, Canada
The report is now acceptable for indexing.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed. Competing Interests:
 27 October 2014 Referee Report
doi:10.5256/f1000research.5910.r6456
  Judit Moldvay
Department of Pulmonology, Semmelweis University, Budapest, Hungary
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 No competing interests were disclosed. Competing Interests:
Version 1
 06 October 2014 Referee Report
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  Judit Moldvay
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It is an interesting work providing new information on the issue of thrombocytosis in colon cancer patients.
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It is an interesting work providing new information on the issue of thrombocytosis in colon cancer patients.
It contains relevant clinicopathologic parameters, however, there is no data on ethnicity, smoking habits,
inflammatory processes, comorbidities, or medications of the studied patients, all which might have
impact on platelet count  . (Msaouel  , 2014) et al.
The main factors that can influence the platelet count should at least be discussed.
In Figure 1. the Authors discussed the mean platelet count according to the depth of tumor invasion.
Although it might change statistically significantly, the mean platelet count remains much within the
normal range, therefore, the conclusion that “… we identified a mild, T stage-dependant increase in mean
platelet count …” is not well-founded. 
One of the most critical aspects of the investigation is the number of patients, especially in stage II, as
disproportionately firm conclusions have been drawn regarding correlation between overall survival and
thrombocytosis on the basis of only four patients with thrombocytosis in stage II.
Another weakness of the study is the lack of information on the precise localizations of the primary
tumors, as this in itself may be of prognostic value, e.g.  .  Majek  (2012) et al. 
Although neoadjuvant treatment has been mentioned, it was not discussed in details, similarly, adjuvant
treatments in advanced cases were not detailed either.These issues should be discussed in the
"Discussion".
In Figure 2. the value of HR is not in accordance with the HR in the legend.
In the 4  line of the Discussion there is a mistake with the Ref. 3., this – most probably – is the Ref. 5.
Similarly, in the 18  line of the Discussion the Ref. 6. – most probably – is the Ref. 8.
In conclusion, this study yielded clinically very interesting results that might have therapeutic
consequence, however, these results need to be confirmed in a much larger cohort of colorectal patients.
All in all, in my opinion this manuscript is acceptable for indexation, but only after corrections and
completions based on the above mentioned comments.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
 No competing interests were disclosed. Competing Interests:
Author Response (   ) 13 Oct 2014 Member of the F1000 Faculty
, Department of Pathology, Monmouth Medical Center, USA Arpad Szallasi
Whereas we share some of the reservations of the referee, we would like to point out that this is an
Observational Study and not a full report. We believe that despite the limitations of this study, this
is an interesting observation with potential implications for patient management. That said, we
wholeheartedly agree with the referee that "these results need to be confirmed in a much larger
cohort of colorectal patients." 
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cohort of colorectal patients." 
Changes done in response to points raised by the referee in the revised MS include:
Our study has a number of limitations such the lack of data on ethnicity, smoking habits,
comorbidities, or medications: this is now clearly stated in Patients and Methods. We
believe that such a detailed, multifactorial analysis would surpass the confines of a
preliminary Observational Report. Of note, the patient database is available for review for
the interested reader (please follow link under Reference 14 to "data source").
 
The most common causes of reactive thrombocytosis are now briefly listed in the
Introduction.
 
The statement between platelet count and depth of invasion has been toned down - the
reference to significance has been eliminated.
 
As emphasized in the MS, our conclusions are preliminary and are based on a limited
number of patients. It is our hope that our findings will be confirmed (or refuted) based on a
much larger patient cohort. 
 
The localization of the primary tumor (right-sided versus left-sided) seems to have no impact
on the presence or absence of thrombocytosis: both groups had an incidence of ~7%. This
is now clearly stated in Results. 
 
References have been corrected.
 None Competing Interests:
 14 August 2014 Referee Report
doi:10.5256/f1000research.5184.r5655
  Ioannis A. Voutsadakis
Medical Oncology, Sault Area Hospital, Ontario, Canada
This is an interesting retrospective study of an extensive series of colorectal cancer patients and authors
are to be congratulated on undertaking this academic endeavour. Nevertheless there are several points
that need to be addressed. A major concern is that all stages of the disease have been included. In
general a comparison between stage I and IV, for example, has no meaning clinically and the only
statement that one can make is that thrombocytosis is more common. Another major concern is that no
multivariate analysis is done or presented.
Some other specific points:
The title mentions specifically stage II disease (as the authors probably recognize the importance
of prognostic factors in this sub-group for therapeutic decisions) but no statistical comparison is
offered anywhere in the article. In any case the number of patients with thrombocytosis in this
group (5) is prohibitive for definite conclusions.
 
In the last line of the Abstract and in the Discussion it should be: “ ” or even better treated as stage III
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1.  
In the last line of the Abstract and in the Discussion it should be: “ ” or even better treated as stage III
“ ” (stage IV patients are treated with palliative intent). considered for adjuvant chemotherapy
 
Data on tumor grade and location have been collected (dataset) but not summarized or presented
in the article. It would be of particular interest to present and include in an eventual multivariate
analysis tumor location (right versus left from the splenic flexure versus rectal).
 
In Patients and methods the normal range of platelets in authors’ institution should be mentioned.
 
In the Results it would be interesting to provide the mean and SD of the platelet number in the 2
groups (normal and thrombocytosis).
 
In fig. 2 there is a discrepancy between HR and p values in the body and the legend. In addition the
numbers at risk do not match. Is that a mistake in calculations or data missing? Authors should
address this.
 
In the 4  line of the 1  paragraph of the Discussion” the reference does not seem to be correct.
Same with reference 6 in the 2 paragraph.
 
In the discussion on metastatic patients - this is an over-simplification. If any useful comparison is
to be made, other data have to be entered in the equation such as oligometastatic versus
polymetastatic disease and treatments.
 
Treatments should be mentioned. For example have all stage III patients received adjuvant
chemotherapy? And have any of the stage II patients received any such treatment?
 
In the 4  paragraph of the Discussion the explanation of “ ” is false negative node examination
improbable as there is no reason to suspect that such false negative occurs more commonly in
patients with thrombocytosis. Instead a difference in biology as briefly discussed in the next
paragraph is more probable.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
 No competing interests were disclosed. Competing Interests:
Author Response (   ) 13 Oct 2014 Member of the F1000 Faculty
, Department of Pathology, Monmouth Medical Center, USA Arpad Szallasi
We are grateful for the referee for his thoughts in making this a better MS. Whereas we agree with
most of the reservations of the referee, we would like to point out that this is an Observation Study,
and not a full report. We believe that despite the limitations of our study, our conclusions are sound
and (if confirmed) may have important implications for patient management.
Major changes done in response to points raised by the referee include:
We agree with the referee that the small number of patients (5) in the stage II group
precludes a definitive conclusion; this is now clearly stated in the MS. Again, this is an
Observational Study within the confines of our hospital database on colorectal carcinoma
th st
nd 
th
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6.  
7.  
8.  
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10.  
Observational Study within the confines of our hospital database on colorectal carcinoma
patients.
 
Both the Abstract and the Discussion have been modified as suggested by the referee
("treated as stage III" has been changed to "may be considered for adjuvant
chemotherapy").
 
The multivariate analysis with special regard to the location of the tumor (right-sided versus
left-sided) in now detailed in the Results.
 
The normal range of platelets at our Institution (150 to 400 K/ul) is now provided in the MS.
 
The mean +/-SD of the platelet counts in the two patient groups (with and without
thrombocytosis) is now provided in Results.
 
Indeed, there is a discrepancy between the body of the text and Figure 2 with regard to the
patient numbers; this should have been addressed before to avoid any confusion. As clearly
stated now in Patients and Methods, our database included 310 patients. Of these patients,
our Cancer Registry had long-term survival data on 253 patients (hence the discrepancy):
the remaining 57 patients most likely decided to seek treatment at a different facility.
 
References have been corrected.
 
Discussion on metastatic patients has been modified.
 
Unfortunately, our Cancer Registry has no full details on chemotherapy regimens (some of
our patients receive chemotherapy in a private practice setting).
 
The reference to "false negative node examination" has been eliminated.
 None Competing Interests:
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